Investment Rating - The report maintains a positive outlook on the industry, indicating a "Buy" rating [11] Core Insights - The beauty industry shows stable growth, with core categories still having room for domestic market penetration. The skincare market is projected to reach CNY 271.2 billion by 2024, with a compound annual growth rate (CAGR) of 2.1% over five years [20][21] - The competitive landscape in beauty can be analyzed through product categories and channels, leading to two main conclusions: established brands with a leading advantage in categories like lotions and serums are likely to maintain their dominance, especially on platforms like Tmall, while brands seeking growth can leverage emerging channels like Douyin [4][10] Summary by Sections Overall Market - The skincare industry is experiencing stable growth, with essential categories such as cleansing, sun protection, and moisturizing products showing strong growth stability. Since 2020, the industry's growth center has shifted downward, highlighting the resilience of these essential categories [20][21] - The domestic penetration rate for face masks, toners, and sun protection has rapidly increased since 2015, while other categories like moisturizers and cleansers still have room for growth [23][26] Category Breakdown - The concentration of leading brands in major categories is increasing, with significant head concentration observed in lotions, masks, and serums. The inter-category linkage rate is improving, particularly for core categories like serums and lotions, which are central to brand strategies [8][30] - The head concentration in the Tmall channel has shown a significant upward trend since 2019, with the exception of cleansers and toners, indicating a "stronger gets stronger" phenomenon [30][65] Channel Comparison - The competitive landscape on Tmall is relatively stable, while Douyin presents structural opportunities for brands with strong operational capabilities. The concentration ratio (CR50) for core categories on Tmall has increased, indicating a stable market structure [9][10] - Brands that have established strong brand recognition in specific categories, such as Proya in lotions and serums, are likely to maintain their leading positions [9][10] Investment Recommendations - The report suggests focusing on two main investment lines: 1. For stable configurations, brands with strong recognition in core categories and a stable Tmall presence, such as Proya and Betaini, present investment opportunities [10] 2. For growth configurations, brands that continue to expand their categories and possess strong operational capabilities on Douyin, such as Shiseido, are recommended [10]

Core Viewpoint - Marubi Biological has officially initiated its secondary listing process in Hong Kong, aiming to become one of the few domestic beauty giants with an "A+H" market presence, despite facing increased competition in the eye care product segment [1] Company Overview - Established in 2002, Marubi focuses on eye care research and gained prominence in 2007 with its popular eye cream, which helped it become the "first eye cream stock" upon its A-share listing in 2019 [1] - Marubi has maintained its position as the top seller in the eye care market in China for three consecutive years from 2021 to 2023 [1] Financial Performance - In 2024, Marubi reported a revenue of 2.97 billion yuan, representing a year-on-year growth of 33.44% - The net profit attributable to the parent company increased by 31.69% to 342 million yuan [1] Marketing and Brand Structure - The company has relied heavily on marketing for growth, with significant expenditures on advertising and traffic, while its research and development investment is relatively low compared to the industry [1] - The main brands "Marubi" and "Lianhuo" are experiencing growth, but the brand "Chunji" has seen a contraction [1] Competitive Landscape - Competitors such as Proya and Winona have launched similar eye care products, which has led to a squeeze on Marubi's market share [1] Regulatory Issues - In late October, Marubi was ordered to rectify issues related to financial accounting, fundraising management, and disclosure, leading to increased uncertainty regarding its IPO in Hong Kong [1]

Group 1 - Alcon (ALC.US) experienced a pre-market drop of over 10% following a downward revision of its 2025 net sales outlook, citing the ongoing impact of U.S. tariffs for the remainder of the year [1] - The company's net sales forecast was adjusted from a range of $10.4 billion to $10.5 billion in May to a new range of $10.3 billion to $10.4 billion [1] - Nearly half of Alcon's revenue is generated from the U.S. market, making it significantly vulnerable to changes in U.S. trade policies [1] Group 2 - As of August 19, Alcon's closing price was $90.00, while the pre-market price on August 20 was $80.83, reflecting a decrease of $9.29 or 10.31% [1] - The company's market capitalization stands at approximately $44.575 billion, with a total share count of 495 million [1] - Alcon's stock has a 52-week high of $100.788 and a low of $80.232, indicating significant volatility in its share price [1]